Macrolide compounds
AssigneeVanderbilt University
InventorsBrian O. BACHMANN, Benjamin REISMAN, Michael SAVONA, Haley RAMSEY, Gary SULIKOWSKI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are macrolide compounds with ATP synthase inhibitory activity. The macrolides may be used to treat cancer and other proliferative disorders. The macrolides may be used to treat leukemia, including acute myeloid leukemia. The macrolides may be used to treat cancer, including AML, in a patient that has developed multidrug resistance. In some embodiments, the macrolide is a derivative of ammocidin A.
Claims26
A compound having the formula:
- or a pharmaceutically acceptable salt thereof,
- wherein
- R1 is selected from H, OH, C1-8alkyl.
- R2 is selected from H, OH, C1-8alkyl.
- R3 is selected from H, OH, C1-8alkyl.
- R4 is selected from H, OH, C1-8alkyl.
- Q1 is a group having the formula:
- wherein
- R2a is selected from —R2a*, —OR2a*, OP(O)(OR2a*)2, OP(O)(OR2a*)(N(R2a*)2, —N(R2a*)2, —N(R2a*)3, —C(O)R2a*, —C(O)OR2a*, —OC(O)R2a*, —OC(O)OR2a*, —NR2a*C(O)R2a*, —C(O)N(R2a*)2, NR2a*C(O)OR2a*, —OC(O)N(R2a*)2, —NR2a*C(O)N(R2a*)2;
- —Cl, —F, —Br, —I, —NO2, —CN, —N3, —(OCH2CH2)m—OH;
- R2a* is in each case independently selected from H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, aryl, C3-10cyclolkyl, C3-10cycloalkenyl, C7-10cycloalkynyl, aryl, C1-10heterocycyl, C1-10heteroaryl;
- wherein each R2a* may be substituted one or more times by —OH, —COOH, —, —PPh3, —CH2NEt3, —CH2NMe3, —NHC(═NH)NH2, a rhodamine dye, a bisquinolinium, —NH2, —Cl, —F, —Br, —I, —NO2, —CN, —N3, PO(OH)2, —(OCH2CH2)m—OH;
- C1-8heterocycyl, aryl, —OC1-8heterocycyl, or C1-8alkoxy,
- wherein any two or more of R2a* may together form a ring;
- R3a is selected from —R3a*, —OR3a*, OP(O)(OR3a*)2, OP(O)(OR3a*)(N(R3a*)2, —N(R3a*)2, —N(R3a*)3—C(O)R3a*, —C(O)OR3a*, —OC(O)R3a*, —OC(O)OR3a*, —NR3a*C(O)R3a*, —C(O)N(R3a*)2, NR3a*C(O)OR3a*, —OC(O)N(R3a*)2, —NR3a*C(O)N(R3a*)2;
- —Cl, —F, —Br, —I, —NO2, —CN, —N3, —(OCH2CH2)m—OH;
- R3a* is in each case independently selected from H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, aryl, C3-10cyclolkyl, C3-10cycloalkenyl, C7-10cycloalkynyl, aryl, C1-10heterocycyl, C1-10heteroaryl;
- wherein each R3a* may be substituted one or more times by —OH, —COOH, —PPh3, —CH2NEt3, —CH2NMe3, —NHC(═NH)NH2, a rhodamine dye, a bisquinolinium, —NH2, —Cl, —F, —Br, —I, —NO2, —CN, —N3, PO(OH)2, —(OCH2CH2)m—OH;
- C1-8heterocycyl, aryl, —OC1-8heterocycyl, or C1-8alkoxy,
- wherein any two or more of R3a* may together form a ring;
- R4a is selected from —R4a*, —OR4a*, OP(O)(OR4a*)2, OP(O)(OR4a*)(N(R4a*)2, —N(R4a*)2, —N(R4a*)3, —C(O)R4a*, —C(O)OR4a*, —OC(O)R4a*, —OC(O)OR4a*, —NR4a*C(O)R4a*, —C(O)N(R4a*)2, NR4a*C(O)OR4a*, —OC(O)N(R4a*)2, —NR4a*C(O)N(R4a*)2;
- —Cl, —F, —Br, —I, —NO2, —CN, —N3, —(OCH2CH2)m—OH;
- R4a* is in each case independently selected from H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, aryl, C3-10cyclolkyl, C3-10cycloalkenyl, C7-10cycloalkynyl, aryl, C1-10heterocycyl, C1-10heteroaryl;
- wherein each R4a* may be substituted one or more times by —OH, —COOH, —PPh3, —CH2NEt3, —CH2NMe3, —NHC(═NH)NH2, a rhodamine dye, a bisquinolinium, —NH2, —Cl, —F, —Br, —I, —NO2, —CN, —N3, PO(OH)2, —(OCH2CH2)m—OH;
- C1-8heterocycyl, aryl, —OC1-8heterocycyl, or C1-8alkoxy;
- wherein any two or more of R4a* may together form a ring;
- R5a is selected from —R5a*, —OR5a*, OP(O)(OR5a*)2, OP(O)(OR5a*)(N(R5a*)2, —N(R5a*)2, —N(R5a*)3, —C(O)R5a*, —C(O)OR5a*, —OC(O)R5a*, —OC(O)OR5a*, —NR5a*C(O)R5a*, —C(O)N(R5a*)2, NR5a*C(O)OR5a*, —OC(O)N(R5a*)2, —NR5a*C(O)N(R5a*)2;
- —Cl, —F, —Br, —I, —NO2, —CN, —N3, —(OCH2CH2)m—OH;
- R5a* is in each case independently selected from H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, aryl, C3-10cyclolkyl, C3-10cycloalkenyl, C7-10cycloalkynyl, aryl, C1-10heterocycyl, C1-10heteroaryl;
- wherein each R5a* may be substituted one or more times by —OH, —COOH, —PPh3, —CH2NEt3, —CH2NMe3, —NHC(═NH)NH2, a rhodamine dye, a bisquinolinium, —NH2, —Cl, —F, —Br, —I, —NO2, —CN, —N3, PO(OH)2, —(OCH2CH2)m—OH;
- C1-8heterocycyl, aryl, —OC1-8heterocycyl, or C1-8alkoxy;
- wherein Rp is in each case selected from H, C1-10alkyl, and aryl;
- wherein any two or more of R5a* may together form a ring;
- wherein any two of more of R2a, R3a, R4a, and R5a may together form a ring;
- Q2 is a group having the formula:
- wherein:
- R1b is selected from H, OH, C1-8alkyl, and OC1-8alkyl;
- R2b is selected from —R2b*, —OR2b*, OP(O)(OR2b*)2, OP(O)(OR2b*)(N(R2b*)2, —N(R2b*)2, —N(R2b*)3, —C(O)R2b*, —C(O)OR2b*, —OC(O)R2b*, —OC(O)OR2b*, —NR2b*C(O)R2b*, —C(O)N(R2b*)2, NR2b*C(O)OR2b*, —OC(O)N(R2b*)2, —NR2b*C(O)N(R2b*)2;
- —Cl, —F, —Br, —I, —NO2, —CN, —N3, —(OCH2CH2)m—OH;
- R2b* is in each case independently selected from H, C1-8alkyl, C1-8alkenyl, C1-10alkynyl, aryl, C3-8cyclolkyl, C3-8cycloalkenyl, C7-10cycloalkynyl, aryl, C1-8heterocycyl, C3-8heteroaryl;
- wherein each R2b* may be substituted one or more times by —OH, —COOH, —PPh3, —CH2NEt3, —CH2NMe3, —NHC(═NH)NH2, a rhodamine dye, a bisquinolinium, —NH2, —Cl, —F, —Br, —I, —NO2, —CN, —N3, PO(OH)2, —(OCH2CH2)m—OH;
- C1-8heterocycyl, aryl, —OC1-8heterocycyl, or C1-8alkoxy,
- wherein any two or more of R2b* may together form a ring;
- R3b is selected from H or a group having the formula:
- wherein
- R3d is selected from H and CH3;
- and
- R4d is selected from H and a group having the formula:
- wherein m is in each case selected from 1-100;
- with the proviso that when all of R2a, R3a, and R4a are OH, R2b is not CH2CH2CH2OCH3.
(canceled)
13-44. (canceled)
49-50. (canceled)
52-53. (canceled)
55-58. (canceled)
A method of treating leukemia in a patient in need thereof, comprising administering ammocidin to the patient.
60-61. (canceled)
63-133. (canceled)
Dependencies are inferred from the claim text.